3 Companies Including MercadoLibre That May Be Trading Below Their Estimated Value
Over the last 7 days, the United States market has dropped 2.6%, yet it remains up 14% over the past year with earnings forecasted to grow by 17% annually. In such a fluctuating environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for growth and stability.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Workday (WDAY) | $168.01 | $334.88 | 49.8% |
| Vishay Precision Group (VPG) | $81.26 | $158.76 | 48.8% |
| Reddit (RDDT) | $177.99 | $354.01 | 49.7% |
| Rayonier (RYN) | $22.18 | $43.04 | 48.5% |
| Neutron Holdings (LIME) | $26.92 | $52.35 | 48.6% |
| Huntington Bancshares (HBAN) | $16.84 | $33.15 | 49.2% |
| FatPipe (FATN) | $5.12 | $10.00 | 48.8% |
| Everpure (P) | $69.25 | $136.03 | 49.1% |
| Dime Commercial Bancshares (DCOM) | $40.60 | $79.24 | 48.8% |
| Beacon Financial (BBT) | $29.84 | $59.28 | 49.7% |
Let's dive into some prime choices out of the screener.
MercadoLibre (MELI)
Overview: MercadoLibre, Inc. operates online commerce platforms in Brazil, Mexico, Argentina, and internationally with a market cap of $94.42 billion.
Operations: The company generates revenue of $31.80 billion from its Internet Software & Services segment.
Estimated Discount To Fair Value: 42.5%
MercadoLibre is trading at US$1,863.31, significantly below its estimated future cash flow value of US$3,242.01, indicating potential undervaluation based on cash flows. Despite a decline in net profit margin from 9.2% to 6%, the company's earnings are forecast to grow significantly at 26.7% annually over the next three years, outpacing the broader US market's growth rate of 16.6%. However, it maintains a high level of debt.
- Our comprehensive growth report raises the possibility that MercadoLibre is poised for substantial financial growth.
- Click here to discover the nuances of MercadoLibre with our detailed financial health report.
Workday (WDAY)
Overview: Workday, Inc. offers enterprise cloud applications globally, with a market cap of approximately $41.47 billion.
Operations: The company generates revenue primarily through its cloud applications segment, which accounts for $9.85 billion.
Estimated Discount To Fair Value: 49.8%
Workday, trading at US$168.01, is priced significantly below its estimated future cash flow value of US$334.88, highlighting potential undervaluation based on cash flows. The company's earnings are forecast to grow 23.37% annually over the next three years, surpassing the broader US market's growth rate of 16.6%. Recent index reclassifications into value benchmarks and strategic partnerships with AWS and Google Cloud enhance its operational capabilities but may also reflect shifting market perceptions.
- The growth report we've compiled suggests that Workday's future prospects could be on the up.
- Unlock comprehensive insights into our analysis of Workday stock in this financial health report.
Eli Lilly (LLY)
Overview: Eli Lilly and Company is involved in the discovery, development, manufacturing, and marketing of human pharmaceutical products across the United States, Europe, China, Japan, and other international markets with a market cap of approximately $1.09 trillion.
Operations: The company's revenue primarily comes from its pharmaceutical products segment, generating $72.25 billion.
Estimated Discount To Fair Value: 26.6%
Eli Lilly, trading below its estimated future cash flow value of US$1,648.59, suggests potential undervaluation based on cash flows. The company's strategic alliances and product advancements bolster its innovative pipeline, enhancing growth prospects. Despite a high debt level, Lilly's earnings are forecast to grow 16.61% annually over the next three years, outpacing the broader US market's growth rate of 16.6%. Recent collaborations in AI-driven drug discovery further strengthen its competitive position in the pharmaceutical industry.
- Insights from our recent growth report point to a promising forecast for Eli Lilly's business outlook.
- Click to explore a detailed breakdown of our findings in Eli Lilly's balance sheet health report.
Key Takeaways
- Dive into all 156 of the Undervalued US Stocks Based On Cash Flows we have identified here.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com